Drug class in one race
VEGFR2 drugs for Non-Small Cell Lung Cancer
2 tracked VEGFR2 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the VEGFR2 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Apatinib vs Ramucirumab